natgillin/translations-raw huggingface dataset:
Advate anvendes til at korrigere manglen på faktor VIII ved at erstatte den manglende faktor VIII, hvorved der opnås midlertidig kontrol med blødningsforstyrrelser.
Advate is used to correct the factor VIII deficiency by replacing the missing factor VIII, giving temporary control of the bleeding disorder.
Advate anvendes til behandling og forebyggelse af blødning hos patienter med hæmofili A (medfødte blødningsforstyrrelser forårsaget af faktor VIII-mangel).
Advate is used for the treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of factor VIII).
Advate bør ikke anvendes af personer, som kan være overfølsomme (allergiske) over for human koagulationsfaktor VIII, muse- eller hamsterproteiner eller nogen af indholdsstofferne.
Advate must not be used in people who are hypersensitive (allergic) to human coagulation factor VIII, to mouse or hamster protein, or to any of the other ingredients.
Advate er beregnet enten til kortvarig eller langvarig behandling.
Advate is intended for either short-term or long-term use.
ADVATE er et hvidt til off-white sprødt pulver.
ADVATE is a white to off-white friable powder.
Advate er pulver og solvens, som blandes til en injektionsvæske, opløsning.
Advate is a powder and solvent that are mixed together to make a solution for injection.
ADVATE er til intravenøs indgivelse efter rekonstitution af præparatet
ADVATE is to be administered intravenously after reconstitution of the product.
Advate givet ved høj dosis er blevet undersøgt for at se, om det virker til nedbrydning af antistoffer mod faktor VIII fra blodet (en proces, der kaldes immuntoleransinduktion), så behandlingen med faktor VIII forbliver effektiv.
Advate given at high dose has been studied to see whether it is effective in clearing antibodies against factor VIII from the blood (a process known as immune tolerance induction) so that treatment with factor VIII remains effective.
ADVATE har ingen indflydelse på din evne til at køre bil, motorcykel eller cykel eller til at arbejde med værktøj og maskiner.
ADVATE has no influence on your ability to drive or to use machines.
ADVATE i BAXJECT III-system: Hver pakning indeholder et BAXJECT III-system klar til brug i en forseglet blisterpakning (hætteglasset med pulver og hætteglasset, der indeholder 2 ml solvens, er på forhånd samlet med systemet til rekonstitution).
ADVATE in BAXJECT III system: Each pack contains a ready to use BAXJECT III system in a sealed blister (the powder vial and the vial containing 2 ml solvent are preassembled with the system for reconstitution).
ADVATE i BAXJECT III-system: Hver pakning indeholder et BAXJECT III-system klar til brug i en forseglet blisterpakning (hætteglasset med pulver og hætteglasset, der indeholder 5 ml solvens, er på forhånd samlet med systemet til rekonstitution)
ADVATE in BAXJECT III system: Each pack contains a ready to use BAXJECT III system in a sealed blister (the powder vial and the vial containing 5 ml solvent are preassembled with the system for reconstitution).
ADVATE i BAXJECT III-system: Hver pakning indeholder et BAXJECT III-system klar til brug i en forseglet blisterpakning (hætteglasset med pulver og hætteglasset, der indeholder 5 ml solvens, er på forhånd samlet med systemet til rekonstitution).
ADVATE in BAXJECT III system: Each pack contains a ready to use BAXJECT III system in a sealed blister (the powder vial and the vial containing 5 ml solvent are preassembled with the system for reconstitution).
Advate indeholder det aktive stof octocog alfa (human koagulationsfaktor VIII).
Advate contains the active substance octocog alfa (human coagulation factor VIII).
Advate indgives som injektion i en vene med en hastighed på 10 ml i minuttet.
Advate is given by injection into a vein at a rate of up to 10 ml per minute.
Advate ligner lægemidlet Recombinate, som er godkendt i Den Europæiske Union (EU), men det fremstilles på en anden måde, så lægemidlet ikke indeholder proteiner af human eller animalsk oprindelse.
Advate is similar to another medicine approved in the European Union (EU) called Recombinate, but it is prepared differently so that there are no human- or animal-derived proteins in the medicine.
ADVATE med BAXJECT II-udstyr: Hver pakning indeholder et hætteglas med pulver, et hætteglas med 2 ml solvens og udstyr til rekonstitution (BAXJECT II).
ADVATE with BAXJECT II device: Each pack contains a powder vial, a vial containing 2 ml solvent and a device for reconstitution (BAXJECT II).
ADVATE med BAXJECT II-udstyr: Hver pakning indeholder et hætteglas med pulver, et hætteglas med 5 ml solvens og udstyr til rekonstitution (BAXJECT II).
ADVATE with BAXJECT II device: Each pack contains a powder vial, a vial containing 5 ml solvent and a device for reconstitution (BAXJECT II).
ADVATE med BAXJECT II-udstyr: Opbevar hætteglasset med lægemidleti den ydre karton for at beskytte mod lys.
ADVATE with BAXJECT II device: Keep the product vial in the outer carton in order to protect from light.
ADVATES immunogenicitet blev vurderet hos tidligere behandlede patienter.
The immunogenicity of ADVATE was evaluated in previously treated patients.
ADVERTENCIA ESPECIAL DE QUE EL MEDICAMENTO DEBE MANTENERSE FUERA DE LA VISTA Y DEL ALCANCE DE LOS NIÑOS
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
Advertencias y precauciones
Warnings and precautions
Advertencias y precauciones especiales de empleo
Special warnings and precautions for use
Advocate bør ikke anvendes til killinger under 9 uger eller til hvalpe under 7 uger.
Advocate should not be used in kittens under 9 weeks of age or in puppies under 7 weeks of age.
Advocate bør ikke kommes i vandløb, da produktet har en skadelig effekt på organismer som lever i vandet: Moxidectin er meget giftigt for organismer der lever i vand.
Advocate should not enter water courses as this may be dangerous for fish and other aquatic organism: moxidectin is highly toxic to aquatic organisms.
Advocate er et lægemiddel, der anvendes til katte, fritter og hunde, der har fået eller er udsat for at få en parasitær blandingsinfektion (dvs. en infektion forårsaget af flere forskellige typer parasitter):
Advocate is a medicine used on cats, ferrets and dogs suffering from, or at risk from, mixed parasitic infections (caused by several different types of parasites):
Advocate fås som spot-on opløsning og leveres i forskellige styrker og pakningsstørrelser alt efter, om det er til katte, fritter eller hunde, og afhængigt af det behandlede dyrs vægt.
Advocate is available as a spot-on solution and comes in different strengths and pack sizes, depending on whether it is for use on cats, on ferrets, or on dogs, and on the size of the animal being treated.
Advocate må ikke udledes i vandløb, da dette kan være farligt for organismer i vandet.
Advocate should not enter water courses as this may be dangerous for fish and other aquatic organisms.
Advocate påføres katten, fritten eller hunden ved hjælp af fyldte spot-on pipetter.
Advocate is applied to cats, ferrets and dogs from pre-filled pipettes.
Advocate spot-on opløsning til
Advocate Spot-on solution for Medium Dogs
Advocate spot-on opløsning til ekstra store hunde
Advocate Spot-on solution for Extra-Large Dogs
Advocate spot-on opløsning til mellemstore hunde
Advocate Spot-on solution for Medium Dogs
Advocate spot-on opløsning til mellemstore hunde
solution for Medium Dogs
Advocate spot-on opløsning til små hunde
Advocate Spot-on solution for Small Dogs
advocate spot-on opløsning til små katte og fritter
Advocate Spot-on solution for Small Cats
Advocate spot-on opløsning til små katte og fritter
Advocate Spot-on solution for Small Cats and Ferrets
Advocate spot-on opløsning til store hunde
Advocate Spot-on solution for Extra-Large
Advocate spot-on opløsning til store hunde
Advocate Spot-on solution for Large Dogs
Advocate spot-on opløsning til store katte
Advocate Spot-on solution for Large Cats
Advocate til ekstra store hunde
Advocate for extra-large dogs
Advocate til ekstra store hunde (> 25-40 kg)
Advocate for extra-large dogs (> 25–40 kg)
Advocate til ekstra store hunde Pipette
Advocate for extra-large dogs Pipette
Advocate til mellemstore hunde
Advocate for medium dogs
Advocate til mellemstore hunde (> 4-10 kg)
Advocate for medium dogs (> 4–10 kg)
Advocate til mellemstore hunde Pipette
Advocate for medium dogs Pipette
Advocate til små hunde
Advocate for small dogs
Advocate til små hunde ( 4 kg)
Advocate for small dogs ( 4 kg)
Advocate til små hunde Pipette
Advocate for small dogs Pipette
Advocate til små katte
Advocate for small cats
Advocate til små katte ( 4 kg) og fritter
Advocate for small cats ( 4 kg) and ferrets
Advocate til små katte og fritter ( 4 kg)
Advocate for small cats and ferrets ( 4 kg)
Advocate til små katte og fritter Pipette
Advocate for small cats and ferrets Pipette
Advocate til store hunde
Advocate for large dogs
Advocate til store hunde (> 10-25 kg)
Advocate for large dogs (> 10–25 kg)
Advocate til store hunde Pipette
Advocate for large dogs Pipette
Advocate til store katte
Advocate for large cats
Advocate til store katte (> 4-8 kg)
Advocate for large cats (> 4–8 kg)
Advocate til store katte Pipette
Advocate for large cats Pipette
Adynamisk knoglesygdom kan opstå, hvis PTH-niveauet konstant undertrykkes til under ca.
Adynamic bone disease may develop if PTH levels are chronically suppressed below approximately
Adækvat kontrolleret thyreoideafunktion (TSH og T4)
Adequately controlled thyroid function (TSH and T4)
Adækvat monitorering af serum- kalium anbefales hos patienter i risikogruppen.
Adequate monitoring of serum potassium in patients at risk is recommended.
AE = bivirkning, aGrad = AE af svær grad, bGrad = AE af moderat og svær intensitet, NRT = nikotinplaster (nicotine replacement therapy patch)
AE, adverse event; aGrade = severe intensity AE; bGrade = moderate and severe intensity AE; NRT=Nicotine replacement therapy patch
Aelurostrongylus abstrusus (voksne)
Aelurostrongylus abstrusus (adult)
aEnhver sværhedsgrad. bGrad 3 = svær smerte med behov for analgetika (eller opioid i ≤ 72 timer) og/eller begrænsning i sædvanlige aktiviteter; Grad 4 = svær smerte med behov for hospitalisering eller forlængelse af hospitalisering, medførende død eller vedvarende
aAny severity grade. bGrade 3= severe pain requiring analgesics (or narcotic analgesics for ≤ 72 hours) and/or limiting usual activities; Grade 4= severe pain requiring hospitalisation or prolongation of hospitalisation, resulting in death, or persistent or significant
Aerinaze 2,5 mg/120 mg tabletter med modificeret udløsning Desloratadin/pseudoephedrin (som sulfat)
Aerinaze 2.5 mg/120 mg modified-release tablets desloratadine/pseudoephedrine sulphate
Aerinaze er en blå og hvid oval tolagstablet med ”D12” præget i det blå lag.
Aerinaze is a blue and white oval bi-layer modified-release tablet with “D12” debossed in the blue layer.
Aerinaze påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj eller betjene maskiner.
Aerinaze has no or negligible influence on the ability to drive and use machines.
Aerinaze tabletternes farmakodynamiske virkning er direkte relateret til komponenternes.
The pharmacodynamic effects of Aerinaze tablets are directly related to that of its components.
Aerius 2,5 mg smeltetabletter
Aerius 2.5 mg orodispersible tablet
Aerius 5 mg filmovertrukne tabletter er pakket i blisterpakninger med 1, 2, 3, 5, 7, 10, 14, 15, 20, 21,
Aerius 5 mg film-coated tablets are packed in blisters in packs of 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30,
Aerius 5 mg smeltetabletter
Aerius 5 mg orodispersible tablet
Aerius 5 mg smeltetabletter
Aerius 5 mg orodispersible tablets
Aerius desloratadin
Aerius desloratadine
Aerius er indiceret hos voksne og unge i alderen 12 år og derover til lindring af symptomer i forbindelse med:
Aerius is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:
Aerius er indiceret hos voksne, unge i alderen 12 år og derover samt børn i alderen 6 til 11 år til lindring af symptomer i forbindelse med:
Aerius is indicated in adults, adolescents aged 12 years and older and children aged 6 – 11 years old for the relief of symptoms associated with:
Aerius er indiceret hos voksne, unge og børn over 1 år til lindring af symptomer i forbindelse med:
Aerius is indicated in adults, adolescents and children over the age of 1 year for the relief of symptoms associated with:
Aerius indeholder desloratadin, som er et antihistamin.
Aerius contains desloratadine which is an antihistamine.
Aerius kan tages med eller uden mad.
Aerius may be taken with or without a meal.
Aerius oral opløsning er pakket i flasker med 30, 50, 60, 100, 120, 150, 225 og 300 ml med børnesikkert låg.
Aerius oral solution is available in bottles of 30, 50, 60, 100, 120, 150, 225 and 300 ml, with a childproof cap.
Aerius oral opløsning leveres i flasker med 30, 50, 60, 100, 120, 150, 225 og 300 ml i type III ravgule glasflasker lukket med et børnesikkert polypropylenskruelåg med en indsats af multi-ply polyethylen.
Aerius oral solution, is supplied in 30, 50, 60, 100, 120, 150, 225 and 300 ml size Type III amber glass bottles closed with a plastic child resistant (C/R) screw closure having a multi-ply polyethylene- faced liner.
Aerius smeltetabletter behøver ikke at blive taget med vand eller væske.
Aerius orodispersible tablet does not need to be taken with water or liquid.
Aerius smeltetabletter indeholder aspartam
Aerius orodispersible tablet contains aspartame
Aerivio Spiromax 50 mikrog/500 mikrog Inhalationspulver.
Aerivio Spiromax 50 micrograms/500 micrograms Inhalation powder
Aerivio Spiromax 50 mikrogram/500 mikrogram inhalationspulver
Aerivio Spiromax 50 microgram/500 microgram inhalation powder
Aerivio Spiromax 50 mikrogram/500 mikrogram inhalationspulver salmeterol/fluticasonpropionat
Aerivio Spiromax 50 microgram/500 microgram inhalation powder salmeterol /fluticasone propionate
Aerivio Spiromax 50 mikrogram/500 mikrogram inhalationspulver salmeterol/fluticasonpropionat
Aerivio Spiromax 50 microgram/500 microgram inhalation powder salmeterol/fluticasone propionate
Aerivio Spiromax er et "hybridt lægemiddel".
Aerivio Spiromax is a ‘hybrid medicine’.
Aerivio Spiromax er et inhalationspulver.
Aerivio Spiromax is an inhalation powder.
Aerivio Spiromax er kun indiceret til voksne i alderen 18 år og derover.
Aerivio Spiromax is indicated for use in adults aged 18 years and older only.
Aerivio Spiromax er kun indiceret til voksne på 18 år og derover.
Aerivio Spiromax is indicated in adults 18 years of age and older only.
Aerivio Spiromax er kun til behandling af patienter med svær astma.
Aerivio Spiromax is for use in patients with severe asthma only.
Aerivio Spiromax indeholder de aktive stoffer salmeterol (en såkaldt langtidsvirkende beta2-agonist) og fluticasonpropionat (et kortikosteroid).
It contains the active substances salmeterol (a so-called long-acting beta-2 agonist) and fluticasone propionate (a corticosteroid).
Aerivio Spiromax indeholder lactose
Aerivio Spiromax contains lactose
Aerivio Spiromax kan påvirke den normale produktion af steroidhormoner i kroppen, især hvis du har taget høje doser i lang tid.
Aerivio Spiromax may affect the normal production of steroid hormones in the body, particularly if you have taken high doses for long periods of time.
Aerivio Spiromax må kun anvendes til at behandle svær astma hos voksne i alderen 18 år og derover samt voksne med KOL.
Aerivio Spiromax should only be used to treat severe asthma in adults aged 18 years and older and adults with COPD.
Aerivio Spiromax påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner.
Aerivio Spiromax has no or negligible influence on the ability to drive and use machines.
Aerivio Spiromax salmeterol/fluticasonproprionat
Aerivio Spiromax salmeterol / fluticasone propionate
Aerivio Spiromax skal inhaleres ned i lungerne gennem munden.
Aerivio Spiromax should be inhaled through the mouth into the lungs.
Aerivio Spiromax skal omgående seponeres og patienten vurderes med iværksættelse af alternativ behandling, hvis det er nødvendigt.
Aerivio Spiromax should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.
Aerivio Spiromax’ sikkerhed og virkning hos børn og unge i alderen under 18 år er ikke klarlagt.
The safety and efficacy of Aerivio Spiromax in children and adolescents aged less than 18 years of age has not been established.
Aerobe Gram-negative bakterier Haemophilus influenzae$* Haemophilus parainfluenzae$ Legionella pneumophila Moraxella catarrhalis*
Aerobic Gram- negative bacteria Haemophilus influenzae$* Haemophilus parainfluenzae$ Legionella pneumophila Moraxella catarrhalis
Aerobe Gram-positive bakterier
Aerobic Gram-positive bacteria
AESI defineres som følgende:
AESIs will be defined as follows:
Aesica Pharmaceuticals GmbH, Alfred-Nobel Strasse 10, D-40789 Monheim am Rhein, Tyskland.
Aesica Pharmaceuticals GmbH, Alfred-Nobel Strasse 10, D-40789 Monheim am Rhein, Germany .
Aesica Queenborough Limited North Road
Aesica Queenborough Limited Queenborough
Aesica Queenborough Limited, North Road, Queenborough, Kent, ME11 5EL, Storbritannien
Aesica Queenborough Limited, North Road, Queenborough, Kent, ME11 5EL, United Kingdom
Aesica Queenborough Limited, Queenborough, Kent, ME11 5EL, Storbritannien
Aesica Queenborough Limited, Queenborough, Kent, ME11 5EL, United Kingdom
Aesica Queenborough Ltd, Queenborough, Kent ME11 5EL, Storbritannien AbbVie Logistics B.V., Zuiderzeelaan 53, 8017 JV Zwolle, Holland
Aesica Queenborough Limited, Queenborough, Kent ME11 5EL, United Kingdom AbbVie Logistics B.V., Zuiderzeelaan 53, 8017 JV Zwolle, The Netherlands
Aesica Queenborough Ltd, Queenborough, Kent ME11 5EL, Storbritannien AbbVie Logistics B.V., Zuiderzeelaan 53, 8017 JV Zwolle, Holland
Aesica Queenborough Ltd, Queenborough, Kent ME11 5EL, United Kingdom AbbVie Logistics B.V., Zuiderzeelaan 53, 8017 JV Zwolle, The Netherlands
AESI’er defineres som følger:
AESIs will be defined as follows:
af
10
af 0,5 ml
0.5 ml
af 14-OH metabolit var
metabolite has reduced activity
Af 190 patienter, der var evaluerbare for så vidt angår objektiv tumorrespons, gennemgik 55 patienter GCTB-operation, og heraf fik 40 komplet resektion.
In 190 subjects evaluable for objective tumour response, 55 subjects had GCTB surgery, out of which 40 subjects had complete resections.
af 3 dage
within 3 days
Af 62 patienter med FVIII:C < 1 % udviklede 19 en inhibitor (31 %).
Of 62 patients with FVIII:C < 1%, 19 developed an inhibitor (31%).
af alle de patienter, der blev behandlet i undersøgelse CAC-91-10-10, havde en enkeltenzymdefekt.
Of all the patients treated in Study CAC-91-10-10, 49 patients presented with a single enzyme defect.
af aminotransferaser anbefales (se
monitoring of transaminases is
af antidepressivummet ud fra en
approach is a dose titration of the
af atazanavir-koncentrationen.
concentrations was observed.
af atazanavir.
atazanavir.
af bedaquilin og lopinavir/ritonavir
the risk, co-administration of
af ciclosporin ved admistration
cyclosporine should be
af CYP3A4, forventes en netto hæmmende
inhibitors of CYP3A4 a net inhibitory
af CYP3A4.
bosentan.
Af de 1.408 patienter, som blev behandlet med nivolumab-monoterapi 3 mg/kg hver 2. uge og undersøgt for antistoffer mod lægemidlet, blev 155 patienter (11,0%) testet positive for behandlingsrelaterede antistoffer, heraf blev 9 patienter (0,6%) testet positive for neutraliserende antistoffer.
Of the 1408 patients who were treated with nivolumab monotherapy 3 mg/kg every 2 weeks and evaluable for the presence of anti-product-antibodies, 155 patients (11.0%) tested positive for treatment-emergent anti-product-antibodies with nine patients (0.6 %) testing positive for neutralising antibodies.
Af de 100 patienter, der var randomiseret til Cosentyx 300 mg, havde henholdsvis 64, 44 og 24 ACR20/50/70-respons.
Of the 100 patients randomised to Cosentyx 300 mg, 64, 44 and 24 had an ACR 20/50/70 response, respectively.
Af de 12 inkluderede patienter responderede 9, en komplet og 8 partielt.
Out of the 12patients enrolled, 9 responded, one completely and 8 partially.
Af de 1226 patienter, der blev randomiseret i studiet, var gennemsnitsalderen 61 år, 58,6 % var mænd, 97,8 % havde en baseline ECOG performancestatus (PS) på 0 eller 1, og 2,2 % havde en baseline ECOG performancestatus (PS) på 2.
Of the 1226 patients randomised in the study, the median age was 61 years, 58.6% were male, 97.8% had a baseline ECOG performance status (PS) of 0 or 1, and 2.2% had a baseline ECOG performance status (PS) of 2.
Af de 126 patienter fik 96 den anbefalede dosis ISENTRESS.
Of the 126 patients, 96 received the recommended dose of ISENTRESS.
Af de 131 patienter, som responderede på induktionsbehandling med ustekinumab og blev randomiseret til placebo-gruppen i starten af vedligeholdelsesstudiet, ophørte respons efterfølgende hos 51 patienter, og disse fik derefter ustekinumab 90 mg subkutant hver 8. uge.
Of 131 patients who responded to ustekinumab induction, and were randomized to the placebo group at the start of the maintenance study, 51 subsequently lost response and received 90 mg ustekinumab subcutaneously every 8 weeks.
Af de 14 patienter med cyanidforgiftning af anden årsag end indånding af røg overlevede de 10, af hvilke syv havde "dødelige" koncentrationer af cyanid i blodet.
Of the 14 patients whose cyanide exposure was due to something other than smoke inhalation, 10 survived, including seven patients with ‘lethal’ levels of cyanide in the blood.
Af de 16 patienter med høje titre fik 15 immuntoleransinduktion (ITI).
Of the 16 patients with high titres, 15 received immune tolerance induction (ITI).
Af de 16 patienter med lave titre, påbegyndtes ITI hos 10.
Of the 16 patients with low titres, ITI was started in 10.
Af de 172 ALK-positive patienter, der blev behandlet med crizotinib i det randomiserede fase 3-studie 1007, var 27 (16%) 65 år eller ældre.
Of 172 ALK-positive patients treated with crizotinib in randomised Phase 3 Study 1007, 27 (16%) were 65 years or older.
Af de 190 patienter med JIA, der blev behandlet med ORENCIA i dette studie, afbrød én (0,5%) patient behandlingen på grund af ikke-konsekutive infusionsrelaterede reaktioner i form af bronkospasme og urticaria.
Of the 190 patients with JIA treated with ORENCIA in this study, one (0.5%) patient discontinued due to non-consecutive infusion reactions, consisting of bronchospasm and urticaria.
Af de 190 patienter, der deltog, fuldførte de 170 periode A, 65% (123/190) fik en ACR Pedi 30- respons og 122 blev randomiseret til periode B. Respons var den samme for alle JIA-undertyper og for patienter med eller uden brug af methotrexat.
Of the 190 patients enrolled, 170 completed Period A, 65% (123/190) achieved an ACR Pedi 30 response, and 122 were randomized to Period B. Responses were similar in all subtypes of JIA studied and for patients with or without methotrexate use.
Af de 195 patienter, der kom fra C04-001, C04-002 og andre indledende studier, indgik Soliris- behandlede PNH-patienter i et langvarigt forlængelsesstudie (E05-001).
From the 195 patients that originated in C04-001, C04-002 and other initial studies, Soliris-treated PNH patients were enrolled in a long term extension study (E05-001).
Af de 2 genotype 1-patienter med virologisk svigt havde den ene patient virus med begyndende NS5A-RAV Y93N, og den anden patient havde virus med begyndende NS5A-RAV’er L31l/V og Y93H ved virologisk svigt.
Of the 2 genotype 1 virologic failure patients, one patient had virus with emergent NS5A RAV Y93N and the other patient had virus with emergent NS5A RAVs L31I/V and Y93H at virologic failure.
Af de 2.712 behandlede patienter var 18% ≥ 65 år, mens 5% var ≥ 75 år.
Of the 2,712 patients treated, 18% were ≥ 65 years of age, while 5% were ≥ 75 years of age.
Af de 20 pædiatriske patienter, som ikke initialt havde hjertestop, overlevede 18 (90 %), heraf 4 med sequelae.
20 paediatric patients without initial cardiac arrest, 18 (90%) survived, of whom 4 with sequelae.